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Abstract Diosmin is a flavonoid often administered in the
treatment of chronic venous insufficiency, hemorrhoids, and
related affections. Diosmin is rapidly hydrolized in the intestine
to its aglicone, diosmetin, which is further metabolized to con-
jugates. In this study, the development and validations of three
new methods for the determination of diosmetin, free and after
enzymatic deconjugation, and of its potential glucuronide me-
tabolites, diosmetin-3-O-glucuronide, diosmetin-7-O-glucuro-
nide, and diosmetin-3,7-O-glucuronide from human plasma
and urine are presented. First, the quantification of diosmetin,
free and after deconjugation, was carried out by high-
performance liquid chromatography coupled with tandem mass
spectrometry, on an Ascentis RP-Amide column (150×2.1 mm,
5 μm), in reversed-phase conditions, after enzymatic digestion.
Then glucuronide metabolites from plasma were separated by
micro-liquid chromatography coupled with tandem mass spec-
trometry on a HALOC18 (50×0.3 mm, 2.7 μm, 90 Å) column,
after solid-phase extraction. Finally, glucuronides from urine
were measured using a Discovery HSF5 (100×2.1 mm, 5 μm)
column, after simple dilution with mobile phase. The methods
were validated by assessing linearity, accuracy, precision, low
limit of quantification, selectivity, extraction recovery, stability,
and matrix effects; results in agreement with regulatory (Food
and Drug Administration and European Medicines Agency)
guidelines acceptance criteria were obtained in all cases. The
methods were applied to a pharmacokinetic study with diosmin
(450 mg orally administered tablets). The mean Cmax of
diosmetin in plasma was 6,049.3±5,548.6 pg/mL. A very good
correlation between measured diosmetin and glucuronide me-
tabolites concentrations was obtained. Diosmetin-3-O-glucuro-
nide was identified as a major circulating metabolite of
diosmetin in plasma and in urine, and this findingwas confirmed
by supplementary experiments with differential ion-mobility
mass spectrometry.
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Introduction
Diosmin is a well-known flavonoid having a broad spectrum of
biological activities, including antioxidant, modulator of capillary
permeability, and anticarcinogenic [1–3], widely used in medi-
cine. Diosmin formulations, orally administered, are employed
for the treatment of chronic venous insufficiency, hemorrhoids,
and venous ulcers (especially of the lower limbs) and the preven-
tion of postoperative thromboembolism [4–7]. It is widely used as
prescription medicine in Europe mainly for its phlebothropic
properties, while in USA is employed as a dietary supplement
Upon ingestion, diosmin is extensively converted to the
aglicone diosmetin (chemical formula in Fig. 1) by intestinal
bacteria [12] and absorbed as such in the organism.
Diosmetin has been found in plasma as glucuronide con-
jugates, like almost all flavonoids [8, 9]; several analytical
methods, with a digestion step to release diosmetin from the
conjugates, have been developed for its quantification [9–13].
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Fig. 1 Chemical structures and MS/MS spectra of diosmetin, 3-O-Gluc, 7-O-Gluc, and 3,7-O-Digluc
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Most authors describe degradation techniques using
glucuronidase-sulfatase enzymes (exception Aidong et al.
[12] using a chemical degradation); however, Werner et al.
published recently a paper raising important concerns on
analytical results because of the heavy contamination with
diosmetin of enzymes originating from snails [13]. As a matter
of fact, extremely different pharmacokinetic (PK) data have
been reported in all these studies and the reality is not clear. It
is also uncertain what diosmetin metabolites are circulating in
body fluids; a single work on identification of diosmetin
conjugates in animal samples has been published [14], and
another paper mentions, without methodological details,
quantitative measurements of diosmetin-3-O-glucuronide (3-
O-Gluc) in human plasma [13] (chemical formulas of the
possible glucuronide metabolites can be seen in Fig. 1).
In the present study, the aspects of diosmetin PK and
metabolism have been reevaluated in order to clarify the
metabolic pathway of this compound and get preliminary
PK data. We describe the development and validation of a
liquid chromatography–mass spectrometry (LC-MS/MS)
method to determine diosmetin in plasma, upon enzymatic
degradation with diosmetin-free glucuronidase and sulfatase.
Following this, another procedure was developed for the
quantitative evaluation of diosmetin glucuronide metabolites
in human plasma; a micro-LC-MS/MS system was found
suitable for obtaining the required selectivity and sensitivity.
The two methods have been applied to a PK study in subjects
treated with diosmin (450 mg per os), in order to measure
diosmetin concentrations and to define the most relevant
type of diosmetin conjugates present in body fluids.
Finally, both methods were adapted to may quantify the
diosmetin metabolites also in urine with and without an
enzymatic step. Diosmetin glucuronides were measured ver-
sus calibration curves in biological material spiked with
synthetic standards. The monoglucuronides are isobaric
and give identical MS/MS fragmentation; since only after
the measurements from plasma have been completed, ion
mobility mass spectrometry (IMS-MS/MS) became avail-
able in our laboratory, supplementary experiments were car-
ried out on urine for confirming the major circulating me-
tabolite. IMS is an excellent tool for the separation of iso-
mers, conformers and isobars as presented in literature [15]
and in all manufacturers’ application notes.
Experimental
Chemicals
Diosmetin (100 %) and paracetamol-3-β-D-glucuronide (100 %)
were purchased from Sigma (Deisenhofen, Germany), while
3-O-Gluc (99.1 %), diosmetin-7-O-glucuronide (7-O-Gluc;
99.2 %), and diosmetin-3,7-O-glucuronide (3,7-O-Digluc;
99.4 %) were from Syncom (Groningen, Netherlands). 13C,D3-
diosmetin (97.5 %) and D4-paracetamol (99.l%) were acquired
from Alsachim (Strasbourg, France) and buprenorphine-3-β-D-
glucuronide (100 μg/mL in methanol) was from Cerilliant
(Round Rock, Texas, USA). All standards used were of analyt-
ical grade quality.
Methanol, acetonitrile, 2-propanol, water (all gradient
grade for LC), ammonium acetate, dimethylsulfoxide (both
analytical grade), formic acid (85 %), and acetic acid
(glacial) were purchased fromMerck (Darmstadt, Germany).
Glucuronidase (from bovine liver), sulfatase (from Abalone
entrails), p-nitrocatecholsulfate, 4-nitrocatechol, and D-
saccharic acid 1,4-lactone monohydrate were provided by
Sigma (Deisenhofen, Germany).
Standard solutions
Diosmetin, 3-O-Gluc, 7-O-Gluc, and 3,7-O-Digluc stock
solutions, at 1 mg/mL, were prepared in dimethylsulfoxide.
The stock solutions of internal standards (13C,D3-diosmetin,
buprenorphine-3-β-D-glucuronide and paracetamol-3-β-D-glu-
curonide were made in methanol. These solutions were pre-
pared each month and stored at −20 °C. Working dilutions in
solvents or plasma were obtained from the stock solutions
when needed.
Calibration curves and quality control samples preparation
In case of diosmetin determinations in plasma, both without
and with enzymatic degradation of the conjugated metabo-
lites, spiked calibration standards (CC) and quality control
(QC) samples were prepared with diosmetin at the following
concentrations in plasma: 0–50–100–250–750–2,000–
6,000–15,000–24,000 pg/mL (CC) and 150–900–9,000–
18,000 pg/mL (QC 1, 2, 3, and 4, respectively).
For the direct quantification of diosmetin glucuronide
metabolites in plasma, calibration curves were built with
3-O-Gluc, 7-O-Gluc, and 3,7-O-Digluc at the same concen-
trations, 0–50–100–300–900–2,500–5,000–10,000–
15,000 pg/mL and QC at 150–3,000–6,000–12,000 pg/mL
(QC 1, 2, 3, and 4, respectively).
For the determination of diosmetin glucuronides in urine,
a higher quantification range was used for all three analytes:
0–1–2.667–8–24–72–210–605–1,000 ng/mL for calibration
curve concentrations and 3–80–400–800 ng/mL for QC 1, 2,
3, and 4 concentrations. In addition, for the measurement of
diosmetin itself, without and with enzymatic digestion, in
urine, calibration curves were spiked at 0–10–25–75–200–
500–1,000 ng/mL (CC) and QC at 30–375–750 ng/mL
(QC 1, 2, and 3, respectively).
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Plasma samples from PK study
A bioavailability study (two periods, two sequences, cross-
over, block-randomized, single-dose design), approved by
the regulatory authorities and Ethical Committee, was
performed in accordance with good clinical practice norms
on 12 healthy volunteers treated orally with diosmin
(450 mg); subjects received a diet poor in flavonoids during
study period (3 days before drug administration and 2 days
after). Blood samples (5 mL each) were collected, using
heparin as anticoagulant (sampling tubes S-Monovette
Hematology 7.5 mL from Sartstedt, Nümbrecht, Germany),
before dosing (0.0) then 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2.0,
2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 16.0, 24.0, and 36.0 h post-dose.
Plasma was separated, within 15 min from sampling, by
centrifugation (5 min, 2,000 rpm) at 4 °C and aliquots (1–
2 mL) were kept frozen at −20 °C until analyzed. Urine
samples were collected just before drug administration
(basal) and then in the intervals 0–4, 4–8, 8–12, 12–16, and
16–24 h after drug administration.
Sample preparation procedures
Enzymatic degradation of plasma samples
In the quantitation experiments based on deconjugation, to
measure diosmetin in plasma, digestion either with β-D-glu-
curonidase, or with sulfatase, or with both enzymes together
was performed. The sample preparation protocol included in
the first step an incubation of a mixture containing 100 μL
plasma, 25 μL glucuronidase, 8 mg/mL (corresponding to an
activity of 113.2 U); 25 μL sulfatase, 50 units/mL; 10 μL
paracetamol-β-D-glucuronide, 10 μg/mL; 40 μL p-
nitrocatechol sulfate, 1 mg/mL (all solutions prepared in so-
dium acetate 0.2 M, pH 4.5); and 200 μL sodium acetate,
0.2 M (pH 4.5), for 12 h at 37 °C, with constant mixing
(Memmert). In these experiments, paracetamol-β-D-glucuro-
nide was added as an internal standard for the control of the
deglucuronidation and p-nitrocatechol sulfate for the control of
the desulfatation, respectively. The same protocol, but without
sulfatase and p-nitrocatechol, was applied to evaluate only the
diosmetin originating from glucuronide metabolites; in other
tests the incubation was repeated also without glucuronidase
and paracetamol-β-D-glucuronide in order to measure only
diosmetin originating from sulfate conjugates (in such cases
D-saccharic acid 1,4-lactone monohydrate was added; 0.02 mL
at a concentration of 35 mg/mL, during incubation, to inhibit
any possible residual glucuronidase activity).
For the calibrators and QC samples, spiked directly with
diosmetin, a deconjugation is not needed; therefore, these
samples were not incubated with enzymes but just diluted
with 0.3 mL sodium acetate 0.2 M, pH 4.5 and further
processed as described in “Extraction procedure for the
determination of diosmetin in plasma.”
Extraction procedure for the determination of diosmetin
in plasma
After enzymatic digestion, plasma samples were centri-
fuged for 1 min at 4,000 rpm. In the case when sulfatase
was used, 0.05 mL of the incubated mixture were trans-
ferred in a mictrotiter plate, treated with 0.05 mL NaOH
1 M and the obtained p-nitrocatechol was measured at
490 nm to appreciate the desulfatation process efficiency
against a standard of p-nitrocatechol in water (concentra-
tion of 0.32 mMol/L, corresponding to the expected levels
of p-nitrocatechol achievable in the samples with a com-
plete enzymatic degradation). Then, in all incubated sam-
ples 0.02 mL internal standard mixture containing 13C,D3-
diosmetin at 200 ng/mL and D4-paracetamol at 2.5 μg/mL
was added, followed by 0.6 mL acetonitrile. Samples were
vortexed for 5 min at 800 rpm, centrifuged 5 min at
4,000 rpm and then 0.8 mL of the clear supernatants were
transferred in clean 2-mL 96-well plates and evaporated at
60 °C under an air stream. The dried extracts were
reconstituted with 0.15 mL methanol/formic acid 0.1 % in
water (1:1, v/v) and injected in the LC-MS/MS system.
Paracetamol (resulted from paracetamol-β-D-glucuronide
degradation) and D4-paracetamol were monitored in the
LC-MS/MS method, and the ratio between them was used
to evaluate the efficiency of the deglucuronidation process,
keeping in mind that equimolar amount of paracetamol and
deuterated-paracetamol were added in the reaction and the
ionization efficiency of the two analytes.
Extraction procedure for the determination of diosmetin–
glucuronide metabolites in plasma
In a separate method, 3-O-Gluc, 7-O-Gluc, and 3,7-O-
Digluc were isolated from plasma by a solid-phase extrac-
tion (SPE) procedure. Plasma (0.25 mL) was mixed with
0.25 mL formic acid 0.5 % in water and with 30 μL internal
standard, buprenorphine-3-β-D-glucuronide solution
20 ng/mL in methanol, then the samples were loaded under
positive pressure onto Isolute C18—100 mg extraction
plates (Biotage, Uppsala, Sweden) already conditioned
with methanol and formic acid 0.5 % in water. The SPE
plates were washed twice with 1 mL formic acid 0.5 % in
water and subsequently the analytes were eluted with
0.5 mL methanol/water (80:20, v/v) in clean 2-mL 96-well
plates. The eluates were evaporated at 60 °C under a stream
of air and reconstituted with 0.15 mL methanol/water (1:1,
v/v) containing 0.1 % formic acid.
L. Silvestro et al.8298
Urine samples processing with enzymatic degradation
In the quantitation experiments based on deconjugation of
diosmetin in urine digestions either with β-D-glucuronidase,
with sulfatase, or with both enzymes together were carried out.
The sample preparation protocol was identical with the one used
for enzymatic degradation of diosmetin conjugates in plasma.
At the end of the incubation period (12 h at 37 °C), to remove
proteins, the samples were added with 0.6 mL acetonitrile,
mixed for 5 min, and centrifuged for 5 min at 4,000 rpm.
Then, 0.2 mL of the clear supernatant were transferred in a clean
2-mL 96-well plate, diluted with other 0.2 mL water containing
0.1 % formic acid and injected in the LC-MS/MS system.
Extraction procedure for the determination of diosmetin
glucuronide metabolites in urine
For the urine samples, a dilute-and-shoot approach was used.
Urine (0.1 mL) was added with 0.1 mL internal standard
solution (paracetamol-3-β-D-glucuronide, 1.5 μg/mL in wa-
ter) and 0.8 mL water/methanol (95:5, v/v) containing 2 %
acetic acid, mixed for 1 min (800 rpm) and centrifuged for
12 min at 4,500 rpm. Then, 0.2 mL of the clear supernatant
were transferred in a clean 2-mL 96-well plate, diluted with
other 0.8 mL water/methanol (95:5, v/v) containing 2 %
acetic acid and injected in the LC-MS/MS system.
Liquid chromatography–mass spectrometry
Three different instrumental set-ups and chromatographic
separations were used in this study. Diosmetin obtained after
enzymatic digestion, both from plasma and urine samples,
was chromatographed on an amide column (Ascentis RP-
Amide 150×2.1 mm, 5 μm, Supelco, Bellefonte, USA)
eluted with a mobile phase gradient (Method 1). Detailed
chromatographic conditions are presented in Table 1. LC-
MS/MS analyses were carried out with an Aria LX-2 system
developed by Cohesive Technologies (Thermo Fisher
Scientific, San Jose, USA), that is integrating through a valve
interface module a HTS PAL autosampler and two binary
gradient pumps Agilent series 1200 SL (Agilent
Technologies, Santa Clara, USA) and allows running two
or more samples in parallel. Mass spectrometric detection
involved a triple quadrupole instrument model API 4000
(AB Sciex, Toronto, Ontario, Canada) operated in positive
electrospray ionization and multiple reaction monitoring
(MRM) mode. The transi t ions 301.11/286.0 and
305.11/286.0 were used to monitor diosmetin and 13C,D3-
diosmetin, respectively, while the paracetamol resulted from
enzymatic degradation and D4-paracetamol were detected on
the transitions 152.02/110.1 and 156.0/114.1, respectively.
Diosmetin glucuronide metabolites extracted from plasma
were separated on a microbore octadecyl column (HALO
C18, 50×0.3 mm, 2.7 μm, 90 Å), maintained at 50 °C and
eluted as described in Table 1 (Method 2). An Ekspert™
micro-LC 200 system from Eksigent Technologies (Dublin,
California, USA), with HTS PAL autosampler (CTC
Analytics, Zwingen, Switzerland), was connected to a triple
quadrupole mass spectrometer model API 5000 (AB Sciex)
equipped with a 50 μm electrospray microprobe. In positive
ionization mode, the chromatographic trace 477.2/301.1 was
used for both 3-O-Gluc and 7-O-Gluc while 3,7-O-Digluc
was monitored on the transition 653.2/301.1 and the internal
standard, buprenorphine-3-β-D-glucuronide, on the transi-
tion 644.3/468.3; the injection volume was 2 μl.
Urine analyses of diosmetin glucuronides were also
performed using a high-throughput high-performance liquid
chromatography (HPLC) system model Aria LX-2 similar to
the one described above. Mass spectrometric detection involved
a quadrupole-linear ion trap instrument model API 5500 QTrap
(AB Sciex) operated in positive electrospray ionization. MRM
transition 476.9/286 was used for 3-O-Gluc and 7-O-Gluc. The
trace 653.1/300.8 was used for 3,7-O-Digluc and the internal
standard of this method, paracetamol-3-β-D-glucuronide, was
measured on the transition 328.04/151.9. Chromatographic sep-
arations were carried out with a pentafluorophenylpropyl col-
umn (Discovery HSF5, 100×2.1 mm, 5 μm—Supelco)
(Method 3, see Table 1); the injection volume was 5 μl.
Acquisitions were triggered 2 min after sample injection and
continued for 4min; an overlapping of approximately 2minwas
obtained with the help of Aria system.
In all aforementioned methods, the eluent from the HPLC
column was introduced in the MS interface without splitting;
research grade nitrogenwas used as curtain and CAD collision
gas while auxiliary and nebulizer were supplied with zero-
grade air. The samples were kept in the autosampler stack
cooled at 10 °C. The optimisation of the mass-dependent
parameters for the analytes and their internal standards was
carried out by infusing directly in the Turboionspray interface
the compounds, diluted at 1 μg/mL (or less if needed) in
water/methanol (1:1, v/v), with the help of a syringe pump
Harvard model “11 PLUS” (Holliston, USA).
Supplementary experiments for the identification of 7-O-
Gluc and 3-O-Gluc were carried out by differential ion-
mobility mass spectrometry, using a SelexION interface
(AB Sciex) on the API5500 QTrap. Solutions of analytes
were infused in the MS source via syringe for parameters
optimization or injected via LC system (Method 3).
Validation procedures
All three methods were validated by assessing selectivity, line-
arity, accuracy, precision, limits of quantification, samples sta-
bility in storage and processing conditions, extraction recovery
andmatrix effects, following EuropeanMedicines Agency 2011
[16] and Food and Drug Administration (FDA) 2001 validation
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guidelines [17]; the FDA/AAPS Crystal City 2007White Paper
recommendations [18] were also considered. The analytical
ranges to be validated were chosen based upon the expected
plasma or urine concentrations as found in literature [12, 13] and
from preliminary experiments. Matrix effects were evaluated
comparing the signal of theoretical QC concentrations prepared
in mobile phase at 100 % recovery, against the signal of the
same concentrations over a blank extract. Matrix factors were
calculated for each compound and internal standards (isotope
labeled in the case of diosmetin) were used for compensating
matrix effects [18, 19].
Results and discussion
Analytical considerations
Diosmetin (chemical structure andMS/MS spectrum in Fig. 1)
is the metabolite of the flavonoid diosmin; compounds of this
class are present in most fruits and vegetables, being absorbed
in humans mainly as aglicones, with food. Several of the
naturally occurring flavonoid molecules have the same mass
of diosmetin (or just a couple of units more like quercetin or
hesperetin) and structures differing by the position of the
double bonds, giving numerous interferences in its measure-
ment. Moreover, most of these flavonoids are also metabo-
lized as glucuronides.
Our first approach focused on diosmetin determination
after enzymatic degradation, and these issues have been
reflected in the impossibility to find a totally free blank matrix
even if the volunteers included in this study have kept a strict
diet. Several stationary phases, from octadecyl (Discovery
HSC18) or pentyl (Bio-Wide Pore C5 150×2.1 mm) to amide
(Discovery RP-Amide 150×2.1 mm) were tested during de-
velopment in order to obtain adequate selectivity from back-
ground. An anion-exchange column (SAX;250×4.6 mm) was
employed in some experiments for the investigation of
diosmetin and metabolites in plasma and urine prior to enzy-
matic digestion. In the end, taking into account the necessity
to use paracetamol as an indicator of deglucuronidation pro-
cess, the amide column gave the best results and it was
preferred for method validation. Chromatograms of extracted
Table 1 Chromatographic conditions used in the three methods








Method 1 Ascentis RP-Amide
150x2.1 mm,
5 μm/Room Temperature
Formic acid 0.1 %
in water
Methanol
400 0.0 70 30
400 0.5 70 30
400 1.0 20 80
400 4.0 20 80
400 4.1 70 30
400 6.0 70 30
Method 2 HALO C18, 50x0.3 mm,
2.7 μm, 90 Å/50ºC
Acetic acid 2 %
in water
Acetic acid 2 %
in acetonitrile
35 0.0 98 2
35 0.3 98 2
35 3.3 75 25
35 3.5 20 80
35 3.8 20 80
35 4.0 98 2
35 6.0 98 2
Method 3 Discovery HSF5, 100x2.1 mm,
5 μm/Room Temperature
Acetic acid 2 %
in water
Acetic acid 2 %
in methanol
400 0.0 100 0
400 1.0 100 0
400 3.5 20 80
400 5.0 20 80
400 5.5 5 95
400 5.6 5 95
400 8.1 100 0
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plasma blank or plasma spiked with diosmetin at low (LLOQ)
and upper limit of quantification (ULOQ) concentrations are
shown in Fig. 2, together with a sample form a treated volun-
teer, processed by enzymatic degradation and extraction.
Incubation times of 12, 24, and 60 h at 37 °C were tested in
order to evaluate the effectiveness of the enzymatic digestion;
an incubation of 12 h proved to be sufficient for optimal
results. Very important for both glucuronidase and sulfatase
digestions was maintaining the pH at 5–5.5, therefore the
amounts of plasma, buffer and enzyme used were studied
carefully until the final protocols presented in paragraph
2.5.1. In all experiments with glucuronidase or
glucuronidase+sulfatase digestions, a ratio paracetamol peak
area/D4-paracetamol peak area >0.75 (corresponding to a
degradation >85 %) was selected as threshold to accept the
individual samples. In case of tests with sulfatase or
sulfatase+glucuronidase the absorbance at 490 nm of the
digested samples had to be at least 85 % of an equimolar
amount of p-nitrocatechol, based on the amount of p-
nitrocatechol sulfate added during incubation.
This analytical method (with enzymatic degradation) was
validated by assessing selectivity, linearity, accuracy, preci-
sion, sensitivity, stability, matrix effects, and extraction re-
covery; data are summarized in Table 2.
As it can be seen, adequate stability, analytical precision–
accuracy, extraction recovery, and matrix effect were obtained.
Regarding selectivity, no measurable peaks were recorded at the
retention time of the analyte and internal standard. Calibration
curves were better calculated using 1/x weighted linear extrap-
olations and r>0.995 were always estimated; at LLOQ levels,
the accuracy estimated in the six plasma samples from different
subjects was 111.8 % with a precision of 6.3 %. To test the
influence of the incubation on diosmetin stability in the spiked
samples, an experiment with incubated QCs 1 and 4, with and
without enzyme, was conducted during validation and the re-
sults are presented in Table 2. The QCs incubated in the protocol
conditions, with all reagents but no enzyme, were back calcu-
lated with good precision and accuracy (±15 %), showing that
the analyte was stable. In the case of incubation with enzyme,
the back calculated concentration at QC 1 was outside the range
Fig. 2 Chromatograms recorded on the MRM transitions of diosmetin
and its internal standard 13C,D3-diosmetin after the injection of blank
(A), calibrators 1 (50 pg/mL) (B) and 8 (24,000 pg/mL) (C) in plasma,
together with a sample from a treated volunteer (D). Column: Discovery
RP-Amide (150×2.1 mm, 5 μm); mobile phase gradient of water with
0.1 % formic acid and methanol. Injection volume: 5 μL. Sample diges-
tion and extraction as described in “Sample preparation procedures”
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(accuracy 139.2 %) as expected, because the endogenous
diosmetin glucuronides from plasma were deconjugated, and
added to the spiked concentration. These results prove that the
approach of not incubating the calibrators and QCs was suitable.
For a comprehensive picture of diosmetin PK, glucuro-
nide metabolites (structures and MS/MS spectra in Fig. 1) in
plasma and urine were measured with two separated
methods. As a comment to Fig. 1, it is important to mention
that no specific fragment ion could be identified to differen-
tiate the two isomers of diosmetin glucuronides, both in
positive and negative ionizations; the fragments coming
from the loss of glucuronide and then from the fragmentation
of diosmetin (in particular by elimination of the methyl group,
methanol, or dioxole) being the most relevant. Figure 3 pre-
sents the chromatograms recorded using a sub-millimeter
column, Halo C18 (0.3×50 mm, 2.7 μm, 90A packing,
Eksigent) eluted at 35 μL/min in gradient with a mobile phase
containing water+0.5 % formic acid and acetonitrile with
0.5 % formic acid. Chromatograms of extracted plasma blank
or plasma spiked with diosmetin glucuronides at LLOQ and
ULOQ concentrations are shown, together with a sample form
a treated volunteer (same sample presented in Fig. 2).
Four peaks were shown to be distinctly separated in the
biological extract within an interval of 0.25 min and diosmetin
glucuronides correctly identified; in these conditions, it was
possible to obtain a clean blank extract from plasma of patients
with special diet. This powerful separation helps in reducing
matrix effects and benefits also from the advantage of very low
flow rate. Mobile phase consisting of ammonium acetate
10 mM and acetonitrile and negative ionization were tested also
with this column but finally the best results in terms of sensitiv-
ity and separation were obtained in acidic conditions, positive
ions mode. The three glucuronides were isolated from plasma
samples by SPE on C18 cartridges in 96-well format as de-
scribed above in the manuscript. Extraction on anion exchange
cartridges (Isolute HAX 100 mg, Biotage, Uppsala, Sweden)
was also tested but the high salt content required for elution was
detrimental for the chromatography on Halo column.
A complete validation was performed for the quantitative
analysis of 3-O-Gluc, 7-O-Gluc, and 3,7-O-Digluc from
plasma; a summary of results is presented in Table 3.
Adequate stability, analytical precision / accuracy and ma-
trix effect were obtained. At LLOQ levels, the accuracy esti-
mated in the six plasma samples from different subjects, was
86.0 % with 19.4 % RSD for 3-O-Gluc, 90.3 % (8.5 % RSD)
for 7-O-Gluc, and 111.0 % (5.9 %RSD) for 3,7-O-Digluc. PK
results measured on real plasma samples will be presented
next (“Results on PK samples from a clinical study”).
In the case of urine metabolites concentrations being 10-
fold higher (based on enzymatic degradation results), a dilute-
and-shoot method was preferred; the microbore column was
replaced with a 2-mm pentafluoropropionyl column
(Discovery HSF5, 10 cm×2.1 mm, 5 μm) eluted also in acidic
conditions as mentioned in “Liquid chromatography–mass
Table 2 Validation parameters of the method for diosmetin quantification from plasma, after enzymatic degradation
Storage and sample handling stability
QC1 QC 2 QC 3 QC 4
Storage conditions (results expressed as % ratio vs. control)
Plasma at −20 C 2 weeks 111.4 (n=6) N/A N/A 100.6 (n=6)
Plasma at −20 C 6 months 104.8 (n=6) N/A N/A 101.8 (n=6)
Plasma freeze-thaw 3 cycles 107.4 (n=6) N/A N/A 99.8 (n=6)
Plasma 2 h room temperature 103.7 (n=6) N/A N/A 100.9 (n=6)
Plasma 6 h room temperature 109.6 (n=6) N/A N/A 100.9 (n=6)
Sample extracts 6 h 10 C 104.7 (n=6) N/A N/A 101.2 (n=6)
Sample extracts 24 h 10 C 108.0 (n=6) N/A N/A 100.4 (n=6)
Precision and accuracy
Within-run mean accuracy (%) 105.8 (N=6) 98.5 (N=6) 101.9 (N=6) 101.8 (N=6)
Within-run precision (RSD%) 2.8 (N=6) 1.3 (N=6) 1.1 (N=6) 2.9 (N=6)
Between-run mean accuracy (%) 103.6 (N=24) 99.3 (N=24) 101.0 (N=24) 101.0 (N=24)
Between-run precision (RSD %) 4.2 (N=24) 1.9 (N=24) 1.7 (N=24) 1.8 (N=24)
Within-run mean accuracy (%) of incubated QC without enzyme 106.6 (N=6) N/A N/A 99.8 (N=6)
Within-run precision (RSD %) of incubated QC without enzyme 2.3 (N=6) N/A N/A 1.0 (N=6)
Within-run mean accuracy (%) of incubated QC with enzyme 139.2 (N=6) N/A N/A 98.8 (N=6)
Within-run precision (RSD %) of incubated QC with enzyme 2.6 (N=6) N/A N/A 0.8 (N=6)
Extraction recovery (% ratio vs. unextracted samples) 68.4 (N=6) N/A N/A 73.5 (N=6)
Matrix effect 0.95 (N=6) N/A N/A 0.94 (N=6)
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spectrometry.” On this stationary phase, buprenorphine-3-
glucuronide was strongly retained and it had to be replaced
with paracetamol-3-glucuronide as internal standard. On the
transition used to detect diosmetin monoglucuronides in plas-
ma, an interfering peak was observed after injecting urine,
thus giving poor chromatographic resolution. In these condi-
tions, a different MRM transition was tested and found suit-
able for this measurement. Relevant chromatograms are
shown in Fig. 4.
For the analysis of urines with enzymatic degradation, the
analytical set up used for plasma was not modified.
Validations of the analytical methods on urine (with and
without enzymatic degradation) were also performed (full
validation for glucuronides determination, partial validation
for diosmetin quantification upon enzymatic digestion; data
presented in Table 4).
Differential ion-mobility mass spectrometry (DMS) was
finally used for the confirmation of 3-O-Gluc as major me-
tabolite excreted in urine. DMS parameters (separation
voltage, compensation voltage, temperature, modifier, and
resolution) were optimized in order to get adequate separa-
tion of the isobaric compounds. The use of specific compen-
sation voltages for each of the isomers along with the MRM
transi t ion permi t ted to discr iminate the two
monoglucuronides and to obtain only one peak on the spe-
cific chromatographic trace, instead of two like in the clas-
sical MRM, thus increasing the selectivity (Fig. 5).
Results on PK samples from a clinical study
Diosmetin determination in plasma after enzymatic
degradation
The mean PK plasma curves of diosmetin obtained from
subjects treated orally with diosmin (450 mg) are presented
in Fig. 6 together with main PK parameters; the data were
obtained analyzing nondigested samples (evaluation of free
diosmetin), following glucuronidase digestion (diosmetin
Fig. 3 Chromatographic traces of 3-O-Gluc and 3,7-O-Digluc after the
injection of blank (a,e), Calibrator 1 (50 pg/mL) (b, f) and Calibrator 8
(15000 pg/mL) (c, g) in plasma, together with a sample from a treated
volunteer (d, h). Column: Halo C18 (0.3×50 mm, 2.7 μm, 90a); mobile
phase gradient of water with 0.5 % formic acid and acetonitrile with
0.5 % formic acid. Injection volume: 2 μL. Sample extraction as
described in “Sample preparation procedures”
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glucuronides levels), sulfatase digestion (diosmetin sulfate
levels), and combined sulfatase with glucuronidase digestion
(total conjugated diosmetin). As it can be seen, no diosmetin
was detected without digestion and as well after sulfatase
degradation. Significant levels were measured after glucuron-
idase and combined sulfatase/glucuronidase degradation; the
levels in these two sets of data were very close, almost
identical.
It is noteworthy that the concentrations measured are quite
close to the ones reported by Wen Aidong et al. and Werner
et al. [12, 13]; a few experiments were conducted also on these
samples using chemical (acidic) degradation, getting very
similar results. On the other side, the data obtained by Cova
et al. [20] or Campanero et al. [10] could not be confirmed. An
optimal enzymatic degradation was obtained as confirmed by
the addition of paracetamol glucuronide and/or nitrocathecol
sulfate.
Diosmetin glucuronides determination in plasma
The mean PK plasma curves of 3-O-Gluc, 7-O-Gluc,
and 3,7-O-Digluc measured in the same samples ana-
lyzed first after enzymatic conjugates degradation are
reported in Fig. 6, together with main PK parameters.
Table 3 Validation parameters
of the method for diosmetin glu-
curonide metabolites quantifica-
tion from plasma
Sample 3-O-Gluc- 7-O-Gluc- 3,7-O-Digluc-
Stability/storage conditions
Plasma at −20 C 1 month QC 1 (n=6) 91.6 104.4 94.5
QC 4 (n=6) 97.3 98.7 104.5
Plasma at −20 C 4 months QC 1 (n=6) 104.8 100.0 98.3
QC 4 (n=6) 91.8 96.9 107.3
Plasma freeze–thaw 3 cycles QC 1 (n=6) 98.4 106.3 93.3
QC 4 (n=6) 96.3 98.7 106.7
Plasma 1 h room temperature QC 1 (n=6) 110.1 108.2 96.5
QC 4 (n=6) 104.1 104.4 112.5
Plasma 4 h room temperature QC 1 (n=6) 105.0 108.0 95.3
QC 4 (n=6) 104.2 106.9 111.8
Sample extracts 8 h room temperature QC 1 (n=6) 94.4 98.2 93.5
QC 4 (n=6) 90.7 94.0 99.1
Sample extracts 36 h room temperature QC 1 (n=6) 86.2 96.2 100.1
QC 4 (n=6) 87.4 85.7 95.7
Precision and accuracy
Within-run mean accuracy (%) QC 1 (n=6) 105.8 104.0 101.7
QC 2 (n=6) 100.7 104.5 112.6
QC 3 (n=6) 99.4 99.4 109.9
QC 4 (n=6) 104.0 107.7 108.7
Within-run precision (RSD %) QC 1 (n=6) 4.2 3.1 13.3
QC 2 (n=6) 3.6 4.4 2.0
QC 3 (n=6) 3.9 3.4 4.0
QC 4 (n=6) 3.0 5.1 6.5
Between-run mean accuracy (%) QC 1 (n=24) 97.1 102.9 99.5
QC 2 (n=24) 98.7 103.1 102.2
QC 3 (n=24) 100.8 102.4 104.2
QC 4 (n=24) 103.9 106.9 104.2
Between-run precision (RSD %) QC 1 (n=24) 12.6 6.8 10.5
QC 2 (n=24) 6.4 5.1 10.3
QC 3 (n=24)) 3.8 4.9 8.4
QC 4 (n=24) 4.8 4.9 6.8
Extraction recovery (%) QC 1 (n=6) 87.4 78.5 47.0
QC 4 (n=6) 93.8 81.9 44.5
Matrix effect QC 1 (n=6) 0.87 1.36 1.05
QC 4 (n=6) 0.89 1.09 1.25
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The highest levels were observed for 3-O-Gluc, while
no measurable levels were detected for 7-O-Gluc. The
diglucuronide of diosmetin was detectable, however, at
very low levels, with concentrations at <5 % of those of
3-O -Gluc and in the AUC0-t calculat ions the
diglucuronide represents only 2.1 % of the total
diosmetin glucuronide AUC0-t.
A mean PK curve obtained from the experiments
performed with glucuronidase digestion (GLUCase
diosmetin trace) is also reported in Fig. 6; data can be easily
compared with the data of total diosmetin glucuronide (sum
of 3-O-Gluc and Dio-3-O-Gluc); these curves are expressed
in pMol/L. As it can be seen, they are very close as further
confirmed by the PK data; the AUC0–t calculated on
diosmetin after glucuronidase digestion is just 3.4 % higher
than the one calculated on the sum of the diosmetine glucu-
ronide metabolites (data calculated on molar basis), such
difference is within the accepted error of the analytical
method.
Diosmetin determination in urine after enzymatic
degradation
Results obtained by the enzymatic degradation approach
on urine samples collected just before and up to 24 hours
following diosmin administration are presented in
Table 5. Levels before drug administration were practi-
cally undetectable and remained quite low up to 4 h
from dosing while high concentrations were obtained in
the following collections both with glucuronidase and
glucuronidase+sulfatase degradation. In case of sulfatase,
only modest levels (<5 % of sulfatase+glucorindase con-
centrations) were observed in the last three urine frac-
tions; no diosmetin concentrations were measured in the
undigested samples. The levels after degradation with
combined glucuronidase+sulfatase were 10–30 % higher
than with glucuronidase only; these results suggest the
presence of mixed conjugates, a fact that was not ob-
served in plasma samples.
Fig. 4 Chromatograms recorded on the MRM transitions of 3-O-Gluc
and 3,7-O-Digluc after the injection of blank (A, E), calibrators 1 (B, F)
and 8 (C, G) in urine, together with a sample from a treated volunteer
(D, H). Column: Discovery HSF5 (10 cm×2.1 mm, 5 μm); mobile
phase gradient of water with 2 % acetic acid and methanol with 2 %
acetic acid. Injection volume, 5 μL. Sample cleanup as described in
“Sample preparation procedures”
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Diosmetin glucuronides determination in urine
Table 5 shows the measured concentrations of the three
glucuronides, the sum of all glucuronide determined, and
the diosmetin levels obtained after glucuronidase and sulfa-
tase degradation. Like in plasma, 3-O-diosmetin glucuronide
was the major metabolite while the 7-O-isomer is practically
absent; the diglucuronide was measured but the levels were
ten times lower compared with the major metabolite.
Table 4 Validation parameters
of the method for diosmetin glu-
curonide metabolites quantifica-
tion in urine. Partial validation of
the method for diosmetin quan-
tification in urine upon enzy-
matic digestion
Sample 3-O-Gluc- 7-O-Gluc- 3,7-O-Digluc-
Stability/storage conditions
Urine at −20 C 1 month QC 1 (n=6) 112.7 106.3 110.4
QC 4 (n=6) 91.7 92.0 95.3
Urine at −20 C 6 months QC 1 (n=6) 112.7 100.5 101.1
QC 4 (n=6) 87.3 87.9 90.0
Urine freeze-thaw 5 cycles QC 1 (n=6) 114.7 108.4 114.6
QC 4 (n=6) 94.6 95.4 95.1
Urine 1 h room temperature QC 1 (n=6) 111.1 114.6 113.2
QC 4 (n=6) 94.4 94.4 94.6
Urine 4 h room temperature QC 1 (n=6) 114.0 108.4 95.3
QC 4 (n=6) 94.0 95.4 114.1
Sample extracts 8 h 10 °C QC 1 (n=6) 108.4 101.1 108.3
QC 4 (n=6) 88.5 88.6 94.3
Sample extracts 36 h 10 °C QC 1 (n=6) 103.5 105.7 95.9
QC 4 (n=6) 86.1 86.9 89.9
Precision and accuracy
Within-run mean accuracy (%) QC 1 (n=6) 103.1 110.4 89.7
QC 2 (n=6) 113.1 112.9 114.0
QC 3 (n=6) 112.1 111.8 109.9
QC 4 (n=6) 94.2 94.0 95.1
Within-run precision (RSD %) QC 1 (n=6) 8.6 11.3 11.6
QC 2 (n=6) 3.4 3.4 4.0
QC 3 (n=6) 0.9 0.8 2.6
QC 4 (n=6) 1.0 2.6 2.5
Between-run mean accuracy (%) QC 1 (n=24) 110.9 107.9 102.6
QC 2 (n=24) 112.3 112.7 112.9
QC 3 (n=24) 111.4 112.8 114.6
QC 4 (n=24) 92.7 93.1 94.0
Between-run precision (RSD %) QC 1 (n=24) 11.2 11.1 13.2
QC 2 (n=24) 3.2 3.5 3.9
QC 3 (n=24)) 2.2 1.7 5.2
QC 4 (n=24) 2.4 2.5 2.8
Extraction recovery (%) QC 1 (n=6) 77.6 76.9 76.7
QC 4 (n=6) 83.3 83.0 82.0
Matrix effect QC 1 (n=6) 0.87 1.36 1.05
QC 4 (n=6) 0.89 1.09 1.25
Partial validation method with enzymatic digestion Diosmetin
Within-run mean accuracy (%) QC 1 (n=6) 109.2
QC 2 (n=6) 101.8
QC 3 (n=6) 90.5
Within-run precision (RSD %) QC 1 (n=6) 9.6
QC 2 (n=6) 3.4
QC 3 (n=6) 2.7
Fig. 5 Chromatographic traces of 3-O-Gluc (A, D), 7-O-Gluc (B,
E), and 3,7-O-Digluc (C, F) after the injection in the ion mobil-
ity-MS interface (SelexION) of a standard mixture (concentration
100 ng/mL) or a urine sample from a treated volunteer. Column:
Discovery HSF5 (10 cm×2.1 mm, 5 μm); mobile phase gradient
of water with 2 % acetic acid and methanol with 2 % acetic acid.
Injection volume, 5 μL. On the top of this figure are presented
the compensation voltage ramp data of each analyte, employed to
define the optimal DMS separation
b
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The comparison of the glucuronide total levels with
those obtained by enzymatic degradation was good
but in some cases differences in the range of 30 %
were observed; most probable matrix effects in the
method without enzymatic degradation were not ade-
quately compensated by the nonlabeled internal
standard.
Analytical methods correlation
The two analytical approaches (enzymatic digestion vs. sum
of the glucuronide concentrations) employed in plasma sam-
ples have been statistically compared by NCSS as shown in
Fig. 6 where a correlation graph between the obtained




Fig. 6 A Mean PK curves of
diosmetin measured in plasma
after enzymatic degradation and
PK parameters obtained on 12
patients orally treated with
diosmin 450 mg in a PK study. B
Mean PK curves of diosmetin
glucuronide metabolites
measured in plasma and PK
parameters obtained on the same
12 patients. C Comparison of
total diosmetin concentrations
obtained with enzymatic
degradation or summing the
measured glucuronide
concentrations (data calculated
on molar basis). The evaluation
was performed by NCSS 2007
software using a standard linear
regression [22] with total
diosmetin glucuronide set as the
independent variable and
diosmetine after glucuronidase
digestion as dependent variable.
Circles represent individual
concentrations measured by LC-
MS/MS. Each scatter plot also
includes linear regression (thick
line) and 95 % confidence
interval for the regression (dotted
lines). R2 (squared correlation
coefficient) represents the
proportion of variation in total
diosmetin that is accounted by
the diosmetin after digestion, and
it is presented here as a ratio.
Slopes were significantly
different from 0 (p <0.005) and
consequently the hypothesis that
slope=0 was rejected. Good R2
values were obtained for
regression: 0.971. Similar data
correlation were obtained
performing Deming regression
with SAS 9.1 software
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(0.971) was obtained for regression. Since typical linear
regression assumes that only one variable can be erro-
neous, the data were also processed in SAS 9.1, using
the Deming regression model in order to validate the
results [21]; a correlation of 0.953 was obtained with
Deming model.
Based on these results, it can be concluded that diosmetin
is essentially present in plasma as 3-O-glucuronide with
minor levels of 3,7-O-diglucuronide while free and sulfates
are absent and combined sulfo-glucurono conjugates are
questionable.
Also in urine 3-O-glucuronide diosmetin is the main
metabolite, while the 7-O-isomer is absent; interestingly,
the levels of diglucuronide were more relevant in urine than
in plasma.
Conclusions
This study reports on the development and validation of
three methods for the determination of diosmetin and
diosmetin glucuronide metabolites from human plasma and
urine. The major circulating metabolite, 3-O-Gluc, was iden-
tified using synthetic standard and confirmed by differential
ion mobility mass spectrometry. To the authors’ knowledge,
this is the first research presenting complete PK of 3-O-Gluc
in plasma and urine.
The application of the enzymatic approach put in
evidence that glucuronide derivatives of diosmetine are
the main metabolites in plasma while sulfates are
undetectable as well as the aglicone alone. The experi-
ments in urine confirmed that glucuronides are the
prevalent metabolites but also small levels of sulfates
were observed and probably mixed conjugate can be
found also in very small amounts; the high solubility
of the sulfate containing metabolites most probably de-
termine a very fast excretion and so far plasma levels
are practically undetectable.
The non-enzymatic method identified 3-O-Gluc as the
main form circulating in plasma while the 7-O-isomer is
absent and the di-glucuronide metabolite is at the levels
of 2 % of the total glucuronide. It is noteworthy that an
optimal correlation was obtained between the analytical
method with enzymatic degradation and the method for
direct determination of diosmetin glucuronides.
Chromatography on sub-millimeter columns and ion
mobility mass spectrometry are novel analytical ap-
proaches that seem to be very promising for quantitative
analysis of complex mixtures and matrices.
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